Preoperative Stereotactic Radiosurgery for Brain Metastases: A Phase 1 Dose Escalation Study Demonstrating Reduced Leptomeningeal Disease
Preoperative SRS to 15 Gy is safe for tumors 2 to 6 cm and significantly reduces nLMD without compromising local control or OS. These findings support preoperative SRS as a viable treatment strategy and justify further investigation into optimal dosing and patient selection.
Authors
- Kristen Owen Riley (ORCID: https://orcid.org/0000-0001-5895-6855)
- Richard A. Popple (ORCID: https://orcid.org/0000-0003-1252-738X)
- Samuel Marcrom (ORCID: https://orcid.org/0000-0002-4014-3781)
- James M. Markert (ORCID: https://orcid.org/0000-0001-7457-7329)
- Christopher D. Willey (ORCID: https://orcid.org/0000-0001-9953-0279)
- Markus Bredel (ORCID: https://orcid.org/0000-0002-7828-0984)
- John B. Fiveash (ORCID: https://orcid.org/0000-0002-1129-2884)
- John M. Hoyle (ORCID: https://orcid.org/0000-0001-8241-8248)
Institutions
- University of Miami (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.adro.2025.101882
- Citations
- 1
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- U.S. Department of Defense
- American Association for Cancer Research
- Gateway for Cancer Research
- Varian Medical Systems
- American College of Radiation Oncology
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health
- EMD Serono
- National Cancer Institute